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Abstract 
Objective: Inflammation plays an important role in lung carcinogenesis. Epidemiologic studies 
have reported inverse associations of non-steroidal anti-inflammatory drug (NSAID) use and 
lung cancer risk. Previously, we found that ever use of glucosamine and chondroitin, which have 
anti-inflammatory properties, were inversely associated with lung cancer risk. After an additional 
year of follow-up, we further examined the association including frequency/duration of use, 
interaction with factors associated with inflammation, and lung cancer histology.  
Methods: Participants were members of the VITamins And Lifestyle (VITAL) Cohort. Adults, 
ages 50-76 years, who were residents of western Washington State, completed a baseline 
questionnaire in 2000-2002 (n=76,904). Participants were queried on their use of glucosamine 
and chondroitin, over the 10 years prior to baseline, and categorized as nonuser, low use <4 
days/week or <3 years, or high use ≥4 days/week and ≥3 years. Lung cancer cases (n=808) were 
ascertained through linkage to the Surveillance, Epidemiology, and End Results cancer registry. 
Results: High 10-year use of glucosamine [Hazard Ratio (HR) 0.77, 95% CI: 0.56-1.07; P-
trend=0.04] but not chondroitin was associated with a reduction in lung cancer risk. The 
association with glucosamine was limited to adenocarcinoma (HR 0.49, 95% CI: 0.27-0.90; P-
trend<0.01), and was not modified by NSAID use or smoking status. 
Conclusions: Our results for glucosamine use are similar to the prior human studies of NSAID 
use and lung cancer, both in magnitude and the limitation of the association to adenocarcinoma. 
Unlike NSAIDs, glucosamine has no known adverse-effects. Although confirmatory studies are 
needed, glucosamine is an attractive candidate for lung cancer chemoprevention. 
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Introduction 
Inflammation plays an important role in cancer etiology and progression at several 
anatomic sites, including the lung (1). Studies of non-steroidal anti-inflammatory drug (NSAID) 
use and lung cancer incidence and death have generally reported inverse associations (2, 3).  
However use of NSAIDs for cancer prevention is not recommended due to their adverse effects 
(4-6).  
Previously, in an exploratory study of 11 non-vitamin, non-mineral “specialty” 
supplements, we reported that ever use of glucosamine and chondroitin supplements over the 10 
years before baseline were inversely associated with the risk of lung cancer in the VITamins And 
Lifestyle (VITAL) cohort study (7). These supplements exhibit anti-inflammatory and anti-
cancer properties in vitro and in vivo (8-11). In Europe, they are approved prescription drugs for 
osteoarthritis; however, in the United States, they fall under the Dietary Supplements health and 
Education (DSHEA) Act, and are sold over-the-counter for “joint health”. They are the most 
commonly used non-vitamin, non-mineral supplements in the United States (12) and have a very 
low risk of adverse effects (13). Here we comprehensively evaluate glucosamine and chondroitin 
use with the risk of lung cancer by examining use by frequency/duration, effect modification by 
factors associated with inflammation, and by histologic subtypes of lung cancer, after an 
additional year of follow-up.  
Materials and Methods 
Study population 
 Participants were members of the VITAL cohort, a study of men and women designed 
specifically to investigate the associations of vitamin, mineral, and specialty supplements with 
cancer risk. Details of the study design and cohort enumeration are given in White et al. (14). 
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Briefly, men and women, 50-76 years of age at baseline, who lived in the 13-county region in 
western Washington State covered by the Surveillance, Epidemiology, and End Results (SEER) 
cancer registry were eligible to participate. Between October 2000 and December 2002, we 
mailed baseline questionnaires and post-card reminders two weeks later to 364,418 names 
purchased from a commercial mailing list. Of these, 77,719 (21.3%) were returned and deemed 
eligible. 
 We excluded participants with a positive or missing history of lung cancer at baseline 
(n=590), participants for whom a lung cancer diagnosis was noted only on the death certificate 
(n=8), as well as diagnoses of lung lymphoma histology (n=2) or in situ lung cancer (n=1). We 
further excluded 214 participants who were missing baseline information on glucosamine and 
chondroitin. After exclusions there were 76,904 participants available for study.   
Data collection 
The baseline questionnaire included a detailed assessment of dietary supplement use. 
Respondents were queried on their use of glucosamine and chondroitin during the 10-year period 
prior to baseline, in addition to use of individual vitamin, mineral, multivitamin, and other 
specialty or herbal supplements. Respondents answered questions about their current and past 
regular use, defined as ≥1 day/week for ≥1 year, of glucosamine and chondroitin. Questions 
included frequency (days/week) and duration (years) of use in the previous 10 years. Participants 
were not queried on dose because no standards exist for accurate dosing of these preparations. 
Although we did not evaluate the validity and reliability of our assessment of reported 
glucosamine or chondroitin use, we assessed the accuracy of 17 vitamin and mineral 
supplements in VITAL in a 3-month test-retest reliability sub-study of 220 randomly selected 
participants; intraclass-correlation coefficients ranged from 0.69 to 0.87 (15).  
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 In addition to supplement use, we collected information at baseline on lung cancer risk 
factors and correlates of supplement use. Participants reported on personal characteristics, 
including height and weight at baseline and at 45 years of age [from which body mass index 
(BMI, kg/m
2
) was computed], family history of lung cancer, medical history, and use of 
NSAIDs. A summary variable for NSAID use included aspirin and non-aspirin NSAIDs and 
excluded low-dose aspirin. Respondents also answered several questions regarding cigarette 
smoking behavior including the age at which they started smoking daily, whether they currently 
smoked at baseline, the number of cigarettes smoked each day, and the cumulative years of 
smoking. From these data, we computed pack-years of smoking and number of years since 
quitting. A summary smoking status variable was also calculated and categorized as never-
smoker, former smoker (quit ≥10 years), recent smoker (quit <10 years), and current smoker.  
Case ascertainment 
 Cohort members were followed for incident lung cancer diagnoses from baseline to 
December 31, 2007, with a mean follow-up time of 6 years. Incident, primary, invasive lung 
cancers were ascertained by linking the study cohort to the western Washington SEER cancer 
registry, which is maintained by the Fred Hutchinson Cancer Research Center. All incident 
cancer cases diagnosed within the 13-county area of western Washington State (except non-
melanoma skin cancer) are reported to SEER along with stage, histologic subtype, and other 
tumor characteristics (16). Cases were ascertained through all area hospitals, offices of 
pathologists, oncologists, and radiotherapists, and from state death certificates. Extensive 
quality-control procedures ensure that registry data are accurate and complete. Linkage to SEER 
is based on ranking of the agreement between characteristics common to VITAL and SEER 
including name, social security number, date of birth, etc.; matches with high concordance were 
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made automatically, while visual inspection was performed for matches in which some, but not 
all criteria matched. 808 incident, invasive lung cancer cases were diagnosed among eligible 
participants between baseline and December 2007.  
Follow-up for censoring 
 Excluding the 1% of the cohort with incident lung cancer, the remaining participants 
were right-censored from the analysis at the earliest date of the following events: date of 
withdrawal from the study (0.02%), date of death (4.9%), date of emigration out of the SEER 
catchment region (5.5%), or December 31, 2007, the most recent date of linkage to the SEER 
registry (89.6%). Deaths that occurred in the cohort were ascertained by linkage to the 
Washington State death file, using procedures similar to the SEER linkage. The National Change 
of Address System and active follow-up by telephone calls and mailings were used to identify 
participants who moved out the study region. 
Statistical analyses 
 Multivariable-adjusted Cox proportional hazards regression models, using participants’ 
age as the time metric, were used to estimate hazard ratios (HR) and 95% confidence intervals 
(CI) for the association of glucosamine and chondroitin with lung cancer risk. We categorized 
glucosamine and chondroitin use in the past 10 years by ever use (nonuser; user: ≥1 day/week for 
≥1 year) and 10-year use (nonuser; low: <4 days/week or <3 years; high: ≥4 days/week and ≥3 
years). All reported P-values are two-sided. P-values for trend (P-trend) were calculated by 
treating categorical variables as ordinal in Cox regression models. 
 We selected a priori potential confounders for adjustment in multivariable models, 
including known or suspected risk factors for lung cancer: age (time variable), race (white, non-
white), education (≤ high school graduate, some college, college or advanced degree), gender 
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(male, female), BMI at baseline (<25.0, 25.0-29.9, ≥30.0 kg/m2), number of first-degree relatives 
with a history of lung cancer (none, 1, ≥2), non-steroidal anti-inflammatory drug (NSAID) use 
(nonuser, low: <4 days/week or <4 years, high: ≥4 days/week and ≥4 years), a history of chronic-
obstructive pulmonary disease and smoking. To accurately control for smoking, we used a step-
wise procedure to select the smoking variables (among pack-years, pack-years squared, years of 
smoking, years of smoking squared, smoking status [4 categories as above] and age when started 
smoking) that were associated with lung cancer risk at the p=0.05 level (17). Our final model 
included years smoked, pack-years, and a squared pack-years term. BMI at baseline, rather than 
at age 45, was included in models as it was the stronger predictor of lung cancer risk. We further 
adjusted proportional hazards models for predictors of glucosamine or chondroitin use, including 
a history of osteoarthritis or chronic joint pain (no, yes), rheumatoid arthritis (no, yes), and use of 
multivitamin supplements (nonuser, former user, current user).  
 We hypothesized a priori that the associations of glucosamine and chondroitin with lung 
cancer risk would be modified by factors associated with inflammation. Therefore, we stratified 
multivariable models on several such factors including NSAID use, BMI at baseline, history of 
osteoarthritis or chronic joint pain, history of chronic-obstructive pulmonary disease, and 
smoking status. We additionally performed stratified analyses on gender, due to gender 
differences in lung cancer incidence rates, and BMI at 45 years of age, a time point that would 
predate the measured use of glucosamine or chondroitin for most participants in the study. P-
values for interaction (P-interaction) were calculated by including a multiplicative term between 
the effect modifier and the dichotomous variable for glucosamine or chondroitin use in the 
unstratified multivariable models. 
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In order to assess whether differences in etiology exist for glucosamine or chondroitin 
exposures in association with biologically defined subsets of lung cancer, we stratified our 
analyses by the most common histologic types: small cell lung cancer (SCLC, n=112), non-small 
cell lung cancer (NSCLC, n=608), including adenocarcinoma (n=280), squamous cell carcinoma 
(n=134), non-small cell lung cancer, not otherwise specified (NSCLC, NOS; n=176), and large 
cell lung cancer (n=18). We further analyzed NSCLC stratified into its major subsets: 
adenocarcinoma, squamous cell carcinoma, and NSCLC, NOS. Excluded from these analyses 
were 88 cases with lung cancers of other histologies.  
Results 
 Characteristics of VITAL participants stratified by glucosamine and chondroitin status 
are given in Table 1. There were only small differences between users and nonusers of 
glucosamine and chondroitin in terms of age, education level, race, BMI, family history of lung 
cancer, and a personal history of chronic-obstructive pulmonary disease. However, glucosamine 
and chondroitin users were substantially more likely to be female, users of NSAIDs and 
multivitamins, and have personal histories of osteoarthritis or chronic joint pain, or rheumatoid 
arthritis. Users of glucosamine and chondroitin were less likely to be current or recent smokers, 
however among ever smokers there were only small differences in mean duration or pack-years 
smoked by glucosamine or chondroitin status.   
 Age and gender-adjusted and multivariable-adjusted associations between glucosamine 
and chondroitin use and lung cancer risk are given in Table 2. Compared to nonuse, use of 
glucosamine was associated with a 20% reduction in lung cancer risk (HR 0.80, 95% CI: 0.65-
0.99) after multivariable adjustment. High 10-year use of glucosamine was associated with a 
linear 23% reduction in risk (HR 0.77, 95% CI: 0.56-1.07; P-trend = 0.04). Use of chondroitin 
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was similarly associated with a 21% reduction in lung cancer risk (HR 0.79, 95% CI: 0.62-1.02); 
however there was no clear trend with 10-year use (P-trend = 0.21). A large proportion of 
glucosamine users were also users of chondroitin. When the analysis of glucosamine was 
restricted to nonusers of chondroitin, glucosamine use was suggestive of an inverse association 
with lung cancer (HR 0.84, 95% CI: 0.61-1.17; data not shown) and high 10-year use of 
glucosamine alone was associated with a 61% reduction in lung cancer risk (HR 0.39, 95% CI: 
0.17-0.86; data not shown); however, the finding was not linear (P-trend = 0.08).     
 There was no effect-modification of the association of glucosamine or chondroitin with 
lung cancer risk, by factors associated with inflammation (Table 3). Although not statistically 
different, the associations appeared stronger among women, participants with a BMI <25.0 at 45 
years of age, a history of osteoarthritis/joint pain, no history of chronic-obstructive pulmonary 
disease, and among long-term (>10 years) quitters rather than current or recent smokers.  
We observed differences in the association of glucosamine and chondroitin use by 
subsets of lung cancer classified by histology (Table 4). Use of glucosamine and chondroitin 
were associated with a reduced risk of NSCLC; this was due to associations limited to 
adenocarcinoma. Glucosamine use was associated with a 36% (HR 0.64, 95% CI: 0.44-0.90) risk 
reduction of adenocarcinoma and chondroitin with a 45% reduction (HR 0.55, 95% CI: 0.35-
0.86). High 10-year average use of glucosamine was associated with a 51% reduction in risk of 
adenocarcinoma (HR 0.49, 95% CI: 0.27-0.90; P-trend<0.01). The p-value for trend of 10-year 
use of chondroitin was 0.03; however the point-estimates show there was no clear trend with 
increasing use. There were no associations of use of these supplements with the other subtypes of 
NSCLC nor with small cell lung cancers.  
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Discussion 
 In this prospective cohort study of 76,904 men and women living in western Washington 
State, we further evaluated our previous findings that use of glucosamine and chondroitin during 
the 10 years prior to baseline was inversely associated with the risk of lung cancer (7). In this 
analysis, we found that the association was limited to adenocarcinomas. While it is difficult to 
separate any associations with glucosamine from those with chondroitin because they are often 
taken together in one pill, the trends with frequency/duration of use were stronger for 
glucosamine than chondroitin overall and for adenocarcinoma, and users of glucosamine only 
had the lowest risk of lung cancer. Factors associated with inflammation did not significantly 
modify the associations.   
 Glucosamine and chondroitin are thought to have anti-inflammatory properties, which 
may explain any protective association with lung cancer. While these supplements have not been 
studied for their relationship to lung cancer except in the VITAL cohort, the association of 
NSAIDs with lung cancer incidence has been studied in this and other prospective studies (18-
29) and one randomized trial (30). Among those that adjusted for smoking, findings have been 
mixed. Similar in magnitude to our findings for glucosamine and chondroitin, we (28) and others 
have reported that use of NSAIDs was associated with 20-40% reductions in lung cancer risk 
(19, 26, 29). In the Women’s Health Study, the only randomized, placebo-controlled trial of 
aspirin that reported on lung cancer risk, Cook et al., (30) reported that women assigned to low-
dose aspirin (100mg), taken every other day, had a borderline statistically significant reduction in 
lung cancer risk (RR 0.78, 95% CI: 0.59-1.03) compared to a placebo. In addition, in a recent 
pooled analysis of 3 randomized trials of aspirin use and risk of cancer death, daily treatment 
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with aspirin for ≥5 years compared to a placebo was associated with a significant reduction in 
lung cancer death after 20 years of follow-up (HR 0.71, 95% CI: 0.58-0.89) (3). 
 We found that use of glucosamine and chondroitin was associated with an approximate 
35-45% reduction in risk of adenocarcinoma, with the greatest reduction (51%) associated with 
high use of glucosamine. Five prospective studies reported on the association of NSAIDs with 
lung cancer stratified by histologic subtypes (19, 21, 23, 24, 28). Because histologic subtypes 
were differently defined between studies, comparisons are somewhat limited. In two studies, 
differences by subtype were reported for NSAIDs that were consistent with our findings for 
glucosamine and chondroitin (19, 28). Akhmedkhanov et al., (19) found that ever use of aspirin 
was associated with a stronger reduction in risk of NSCLC (OR 0.39, 95% CI: 0.16-0.96) than 
lung cancer risk overall (OR 0.66, 95% CI: 0.34-1.28). Slatore et al., (28) reported that NSAID 
use was associated with strong reductions in risk of NSCLC overall (10-year average use >4.2 
days/week vs. non-use: HR 0.68, 95% CI: 0.51-0.92; P trend=0.01) and adenocarcinoma in 
particular (HR 0.59, 95% CI: 0.37-0.94; P-trend=0.01), but not squamous or small cell lung 
cancers in the VITAL cohort, similar to our results for glucosamine and chondroitin. In two other 
studies, NSAIDs were not associated with lung cancer risk and no differences were reported by 
lung cancer subtype (21, 24). In the remaining study, NSAIDs were positively associated with 
lung cancer risk, with no differences by subtype; however, the authors did not adjust for smoking 
(23). Finally, in the recent pooled analysis of randomized trials mentioned above, the effect of ≥5 
years of aspirin use on lung cancer death was restricted to adenocarcinomas (HR 0.55, 95% CI: 
0.33-0.94) (3), highly consistent with our result for high use of glucosamine. Biomarkers of 
inflammation are expressed at greater levels in lung adenocarcinomas than other histologies (1, 
31), suggesting that inhibiting inflammation may differentially reduce adenocarcinoma incidence.   
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Glucosamine and chondroitin have been shown to reduce the expression of inflammatory 
genes and inhibit cell proliferation through inhibition of the transcription factor NFκB in vitro 
and in vivo (8-11); these effects are associated with lower cancer risk (32). Glucosamine inhibits 
synthesis of pro-inflammatory mediators including IL-1 beta in human osteoarthritic 
chondrocytes (9), and chondroitin reduces expression of pro-inflammatory cytokines (e.g., IL-1, 
TNF-α) and enzymes with pro-inflammatory activity (e.g., COX2, VCAM-1) (8). There is indirect 
evidence from randomized trials that support the efficacy of glucosamine and chondroitin in 
reducing pain and improving function in osteoarthritis patients (13, 33-37); however we are 
unaware of any studies which demonstrate direct anti-inflammatory effects of glucosamine and 
chondroitin in humans. 
 This study has several strengths. The VITAL study is the first prospective study designed 
to investigate the association of specialty supplements with cancer risk. Supplement users were 
targeted for recruitment, and we had detailed assessment of glucosamine and chondroitin use 
over a sufficiently long time period (10 years before baseline) that could plausibly influence 
cancer risk. In addition, we collected extensive information on cancer risk factors, and we were 
able to carefully control for the confounding effect of smoking history. We were also able to 
adjust for correlates of supplement use, thereby correcting for potential confounding by 
indication. Another strength of this study was our ability to report associations with lung cancer 
histologies beyond comparisons of small cell and non-small cell tumors. Lastly, follow-up on the 
cohort was 95% complete; therefore, selection bias due to loss to follow-up is not likely to 
explain our findings.  
 This study also has several limitations. Foremost, we did not ascertain information on the 
dose of glucosamine or chondroitin that was taken, which would contribute to measurement 
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error. The recommended daily dose on the bottle labels is in the range of 500-1500mg 
glucosamine sulfate or hydrochloride typically with 400-1200mg chondroitin sulfate. 
ConsumerLab.com, which independently tests supplements for manufacturers and consumers, 
found that among 37 glucosamine and chondroitin supplements tested only 2 products (5%) 
contained <94% of the stated dose of chondroitin and all contained at least the stated dose of 
glucosamine (38). Other limitations of this study are that the supplement exposure data were 
ascertained by self-report and we were not able to update exposure information prospectively. 
Due to the prospective nature of the study, we expect that any exposure measurement error 
would be non-differential and would result in attenuated point-estimates.  
 In summary, we found that use of glucosamine and chondroitin was associated with 
reduced risk of lung cancer overall, and lung adenocarcinomas in particular; with long-term use 
of glucosamine conferring the greatest benefit. The association with glucosamine was of similar 
or stronger magnitude as those reported for NSAIDs. Furthermore, our result for glucosamine 
was limited to lung adenocarcinomas, the lung cancer histology that has been shown to be 
reduced in randomized trials of aspirin (3). Unlike NSAIDs (4-6, 39), glucosamine is considered 
safe and has no known side-effects (13). Although more research is needed on mechanisms of 
action, should these findings be replicated, they would suggest glucosamine would make an 
attractive candidate for chemoprevention.   
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Table 1. Baseline characteristics of VITAL participants by glucosamine and chondroitin status (n=76,904). 
Characteristic Glucosamine  Chondroitin 
 User (n=15,546),% Nonuser (n=61,302), %  User (n=10,423), % Nonuser (n=66,481), % 
Age (years)      
 <55 18.8 24.4   17.4  24.1 
 55 to <60 21.6 23.0   21.0  22.9 
 60 to -<65 19.4 17.9   20.0  17.9 
  65 to <70 18.4 16.0   18.9  16.1 
 ≥70 21.7 18.8   22.7  18.9 
Education      
 ≤High school graduate 17.0 20.9   16.4  20.7 
 Some college 39.3 38.0   38.6  38.2 
 College or advanced degree 43.7 41.1   45.1  41.1 
Race      
 White 94.2 92.9   94.6  92.9 
 Non-white 5.8 7.1   5.4  7.1 
Gender      
 Male 38.7 50.5   37.8  49.7 
 Female 61.4 49.5   62.2  50.3 
Body mass index (kg/m
2
)      
 <25.0 34.5 34.4  34.2  34.4 
 25.0 to 29.9 40.1 41.3   39.9  41.2 
 ≥30.0 25.5 24.4   25.9  24.4 
Smoking status      
 Never 50.1 47.2   50.0  47.5 
 Former (≥10 years since quit) 40.0 36.5   40.3  36.7 
 Recent (<10 years since quit) 5.4 6.9   5.2  6.8 
 Current 4.9 9.3  4.5  9.0 
Duration of smoking (years)
a 
      
 Mean (SD) 21.0 (13.1) 23.4 (13.6)  20.9 (13.0) 23.3 (13.6) 
Cigarette pack-years
a
      
 Mean (SD) 23.1 (21.8) 26.7 (23.6)  23.2 (21.6) 26.5 (23.5) 
Number of first-degree relatives with  lung cancer    
 None 87.2 87.4   87.0 87.4 
 1 11.8 11.8   12.0 11.7 
 ≥2  0.9 0.9  0.9 0.9 
NSAID use
b,c
      
 Nonuser 39.4 55.1  37.3 54.2 
 Low 36.0 27.6  36.8  28.1 
 High 24.6 17.3  25.9  17.7 
 21 
Multivitamin use      
 Nonuser  16.7  39.1   16.4  37.4 
 Former  7.5  7.7  7.5  7.7 
 Current  75.9  53.2   76.1  54.9 
Chronic-Obstructive Pulmonary Disease     
 No  96.7  96.4   96.7  96.4 
 Yes  3.3  3.6   3.4  3.6 
Osteoarthritis or chronic joint pain      
 No  29.3  57.3   26.7  55.5 
 Yes  70.7  42.7   73.3  44.5 
Rheumatoid arthritis      
 No  94.8  96.4   94.9  96.3 
 Yes  5.2  3.6  5.1  3.7 
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; 
a
 Among current and former smokers 
b 
Includes aspirin, ibuprofen, celecoxib, rofecoxib, and other pain relievers such as indomethacin and piroxicam (women only) 
c 
10-year use: Nonuser; low use, <4 days/week or <4 years; high use, ≥4 days/week and ≥4 years 
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Table 2. Associations between glucosamine and chondroitin and lung cancer risk among VITAL participants (n = 76,904). 
Supplement 
 
Cases 
(n = 808), n (%)  
Non-cases 
(n = 76,097), n (%) 
Age & Gender-adjusted 
HR (95% CI) 
Multivariable-adjusted 
HR (95% CI)
a
 
     
Glucosamine     
 Nonuser 691 (85.63) 60,611 (79.71) 1.00 (reference) 1.00 (reference) 
 User 116 (14.37) 15,430 (20.29) 0.62 (0.51-0.76) 0.80 (0.65-0.99) 
10-year use
b
     
 Nonuser 691 (85.63) 60,611 (79.71) 1.00 (reference) 1.00 (reference) 
 Low 73 (9.05) 9,899 (13.02) 0.64 (0.50-0.81) 0.82 (0.63-1.06) 
 High 43 (5.33) 5,531 (7.27) 0.60 (0.44-0.82) 0.77 (0.56-1.07) 
 P trend   <0.0001 0.04 
     
Chondroitin     
 Nonuser 732 (90.71) 65,749 (86.40) 1.00 (reference) 1.00 (reference) 
 User 75 (9.29) 10,348 (13.60) 0.60 (0.48-0.77) 0.79 (0.62-1.02) 
10-year use
b
     
 Nonuser 732 (90.71) 65,749 (86.40) 1.00 (reference) 1.00 (reference) 
 Low 40 (4.96) 6,718 (8.83) 0.52 (0.37-0.71) 0.69 (0.50-0.95) 
 High 35 (4.34) 3,630 (4.77) 0.75 (0.54-1.06) 0.96 (0.67-1.37) 
 P trend   <0.001 0.21 
Abbreviations: HR, Hazards Ratio; CI, Confidence Interval 
 
a
 Adjusted for age, race, education, gender, body mass index, family history of lung cancer, non-steroidal anti-inflammatory 
drug use, years smoked, pack-years, pack-years squared, chronic-obstructive pulmonary disease, multivitamin use, joint 
pain or osteoarthritis, and rheumatoid arthritis 
 
b 
10-year use: Nonuser; low use, <4 days/week or <3 years; high use, ≥4 days/week and ≥3 years 
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Table 3. Associations between glucosamine and chondroitin with lung cancer risk, stratified by inflammation-associated conditions among VITAL participants (n=76,904). 
 Glucosamine  Chondroitin 
 Nonuser  User  Nonuser  User 
 Cases/non-cases HR (95% CI)a  Cases/non-cases HR (95% CI)a  Cases/non-cases HR (95% CI)a  Cases/non-cases HR (95% CI)a 
Gender            
 Male 387/30,577 1.00 (reference)  61/5,947 0.99 (0.74-1.32)  412/32,631 1.00 (reference)  36/3,901 0.91 (0.64-1.30) 
 Female 304/30,034 1.00 (reference)  55/9,483 0.64 (0.47-0.87)  320/33,118 1.00 (reference)  39/6,447 0.68 (0.49-0.96) 
 P-interaction     0.12      0.41 
NSAID Use (10 year use)b            
 Nonuser 340/30,843 1.00 (reference)  44/5,699 0.85 (0.61-1.19)  357/32,934 1.00 (reference)  27/3,628 0.84 (0.56-1.25) 
 Low 162/15,423 1.00 (reference)  34/5,223 0.65 (0.43-0.96)  175/17,070 1.00 (reference)  21/3,590 0.55 (0.36-0.91) 
 High 135/9,652 1.00 (reference)  30/3,566 0.89 (0.59-1.35)  143/10,709 1.00 (reference)  22/2,521 0.99 (0.62-1.58) 
 P-interaction     0.99      0.75 
Body Mass Index            
 <25.0 246/19,766 1.00 (reference)  39/5,089 0.80 (0.56-1.14)  261/21,480 1.00 (reference)  24/3,396 0.80 (0.52-1.23) 
 ≥25.0 401/37,779 1.00 (reference)  73/9,663 0.84 (0.65-1.10)  427/40,954 1.00 (reference)  47/6,520 0.82 (0.60-1.11) 
 P-interaction     0.69      0.81 
Body Mass Index at 45 years            
 <25.0 418/31,614 1.00 (reference)  62/8,471 0.73 (0.55-0.97)  440/34,388 1.00 (reference)  237/27,842 0.75 (0.54-1.05) 
 ≥25.0 220/25,736 1.00 (reference)  47/6,243 0.98 (0.70-1.37)  40/5,718 1.00 (reference)  30/4,168 0.92 (0.62-1.36) 
 P-interaction     0.07      0.20 
Osteoarthritis or chronic  joint pain            
 No 358/34,753 1.00 (reference)  34/4,520 1.06 (0.74-1.53)  371/36,531 1.00 (reference)  21/2,762 1.09 (0.70-1.70) 
 Yes 333/25,841 1.00 (reference)  82/10,910 0.71 (0.55-0.91)  361/29,200 1.00 (reference)  54/7,586 0.69 (0.51-0.94) 
 P-interaction     0.11      0.14 
Chronic-Obstructive Pulmonary Disease           
 No 569/58,492 1.00 (reference)  97/14,941 0.78 (0.62-0.98)  603/63,478 1.00 (reference)  63/10,011 0.78 (0.59-1.02) 
 Yes 122/2,102 1.00 (reference)  19/489 0.94 (0.57-1.57)  129/2,253 1.00 (reference)  12/337 0.91 (0.49-1.68) 
 P-interaction     0.81      0.98 
Smoking            
 Former smoker (≥10 years quit) 278/21,860 1.00 (reference)  56/6,054 0.78 (0.57-1.05)  299/23,813 1.00 (reference)  35/4,128 0.71 (0.50-1.03) 
 Current/Recent smoker (<10 years quit) 352/9,487 1.00 (reference)  51/1,527 0.95 (0.69-1.29)  369/10,046 1.00 (reference)  34/973 1.01 (0.70-1.45) 
 P-interaction     0.61      0.13 
Abbreviations: HR, Hazards Ratio; CI, Confidence Interval, COPD, chronic-obstructive pulmonary disease 
 
a Adjusted for age, race, education, gender, body mass index, family history of lung cancer, non-steroidal anti-inflammatory drug use, years smoked, pack-years, pack-years squared, chronic-obstructive pulmonary disease, 
multivitamin use, joint pain or osteoarthritis, and rheumatoid arthritis 
 
b 10-year use: Nonuser; low use, <4 days/week or <4 years; high use, ≥4 days/week and ≥4 years 
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Table 4. Associations between glucosamine and chondroitin and risk of lung cancer, by histologic type (n = 76,904). 
Supplement 
 
NSCLC,  
n = 608 cases 
 SCLC,  
n = 112 cases  
 Total NSCLC
c
 
n = 608 
HR (95% CI)
a
 
Adenocarcinoma,  
n = 280 cases 
HR (95% CI)
a
 
Squamous Cell Carcinoma,  
n = 134 cases 
HR (95% CI)
a
 
NSCLC, NOS;  
n = 176 cases 
HR (95% CI)
a
 
  
 
HR (95% CI)
a
 
       
Glucosamine       
 Nonuser 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)  1.00 (reference) 
 User 0.77 (0.60-0.98) 0.64 (0.44-0.90) 0.99 (0.60-1.65) 0.88 (0.56-1.38)  1.01 (0.60-1.72) 
       
10-year use
b
       
 Nonuser 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)  1.00 (reference) 
 Low 0.72 (0.53-0.98) 0.71 (0.47-1.08) 0.60 (0.28-1.31) 0.77 (0.43-1.38)  1.29 (0.72-2.31) 
 High 0.85 (0.60-1.21) 0.49 (0.27-0.90) 1.60 (0.86-2.96) 1.05 (0.56-1.97)  0.58 (0.21-1.59) 
 P trend 0.09 <0.01 0.57 0.79  0.61 
       
Chondroitin       
 Nonuser 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)  1.00 (reference) 
 User 0.70 (0.52-0.94) 0.55 (0.35-0.86) 1.04 (0.57-1.88) 0.70 (0.39-1.25)  1.01 (0.54-1.88) 
       
10-year use
b
       
 Nonuser 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)  1.00 (reference) 
 Low 0.52 (0.34-0.79) 0.47 (0.26-0.85) 0.52 (0.19-1.43) 0.52 (0.23-1.18)  1.09 (0.52-2.29) 
 High 1.01 (0.68-1.49) 0.69 (0.36-1.31) 1.86 (0.93-3.74) 1.00 (0.46-2.16)  0.88 (0.32-2.43) 
 P trend 0.15 0.03 0.86 0.58  0.93 
Abbreviations: NSCLC, non-small cell lung cancer; NOS, not otherwise specified; SCLC, small cell lung cancer; HR, Hazards Ratio; CI, Confidence Interval;  
 
a
 Adjusted for age, race, education, gender, body mass index, family history of lung cancer, non-steroidal anti-inflammatory drug use, years smoked, pack-years, 
pack-years squared, chronic-obstructive pulmonary disease, multivitamin use, joint pain or osteoarthritis, and rheumatoid arthritis 
 
b 
10-year use: Nonuser; low use, <4 days/week or <3 years; high use, ≥4 days/week and ≥3 years 
 
c
 Includes adenocarcinomas, squamous cell carcinomas, large cell lung cancers, and NSCLC, NOS 
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